Programs 2017-04-12T11:38:32+00:00


The Transcend platform has been shown to effectively shuttle antibodies, biological agents, enzymes and small molecules drugs across the blood brain barrier, enter into specific brain cells and localize in the appropriate intracellular compartments.

Areas of research

First Generation: MTf

Brain Cancer

Breast Cancer Metastases in the Brain

  • MTf + Herceptin® (transtuzumab)
  • MTfp + Herceptin® (transtuzumab)


Doxorubicin & Paclitaxel Proof of Concept Study

  • MTf + Doxorubicin
  • MTf + Paclitaxel


Metabolic Diseases

MPSl – Hurler Syndrome

  • Transcend + iduronate-2-sulfatase (“IDS”)

MPSll – Hunters Syndrome

  • MTf + iduronate-2-sulfatase (“IDS”)
  • MTfp + iduronate-2-sulfatase (“IDS”)

Neurodegenerative Disease

Alzheimer’s Disease

  • MTf + Anti-Amyloid Beta (“Aβ”) Antibody


Second Generation: MTfp & siRNA

To be announced